Squalene monooxygenase catalyzes the epoxidation of C-C double bond of squalene to yield 2,3-oxidosqualene, the key step of sterol biosynthesis pathways in eukaryotes. Sterols are essential compounds of these organisms and squalene epoxidation is an important regulatory point in their synthesis. Squalene monooxygenase downregulation in vertebrates and fungi decreases synthesis of cholesterol and ergosterol, respectively, which makes squalene monooxygenase a potent and attractive target of hypercholesterolemia and antifungal therapies. Currently some fungal squalene monooxygenase inhibitors (terbinafi ne, naftifi ne, butenafi ne) are in clinical use, whereas mammalian enzymes ' inhibitors are still under investigation. Research on new squalene monooxygenase inhibitors is important due to the prevalence of hypercholesterolemia and the lack of both suffi cient and safe remedies. In this paper we (i) review data on activity and the structure of squalene monooxygenase, (ii) present its inhibitors, (iii) compare current strategies of lowering cholesterol level in blood with some of the most promising strategies, (iv) underline advantages of squalene monooxygenase as a target for hypercholesterolemia therapy, and (v) discuss safety concerns about hypercholesterolemia therapy based on inhibition of cellular cholesterol biosynthesis and potential usage of squalene monooxygenase inhibitors in clinical practice. After many years of use of statins there is some clinical evidence for their adverse effects and only partial effectiveness. Currently they are drugs of choice but are used with many restrictions, especially in case of children, elderly patients and women of childbearing potential. Certainly, for the next few years, statins will continue to be a suitable tool for cost-effective cardiovascular prevention; however research on new hypolipidemic drugs is highly desirable. We suggest that squalene monooxygenase inhibitors could become the hypocholesterolemic agents of the future.
Introduction: squalene monooxygenase
Squalene monooxygenase (squalene epoxidase, SE, EC 1.14.99.7), the enzyme of cholesterol synthesis pathway, was detected in rat liver microsomes in 1969 (Yamamoto and Bloch , 1970 ) . Then it was discovered in fungi as an enzyme taking part in ergosterol synthesis and in plants, where it is a part of phytosterols synthesis pathways (Petranyi et al. , 1984 ; Godio et al. , 2007 ; Rasbery et al. , 2007 ; Uchida et al. , 2007 ; He et al. , 2008; Han et al. , 2010 ) . SE was also identifi ed in some bacteria which produce pentacyclic triterpens instead of sterols, so-called hopanoids synthesized from squalene by squalene-hopene cyclase (SHC) (EC 5.4.99.17) (Nakano et al., 2003; Pearson et al. , 2003 ; Volkman , 2003 ; Nakano et al. , 2007 ) . Several years of investigations aimed at fi nding inhibitors of pathogenic fungi SE resulted in numerous antimycotics [e.g., terbinafi ne (Ryder , 1989 ) ], which are stiil in clinical use today (Berg and Plempel , 1989 ) .
Squalene monooxygenase belongs to the fl avoprotein monooxygenase family, which catalyze a wide variety of oxidative reactions (van Berkel et al., 2006; Joosten and van Berkel , 2007 ) . SE catalyzes squalene epoxidation. Reaction occurs in the presence of fl avin adenine dinucleotide (FAD), molecular oxygen, nicotinamide adenine dinucleotide phosphate (NADPH), NADPH-cytochrome P-450 reductase (EC 1.6.2.4), and the supernatant protein factor (Tai and Bloch , 1972 ; Shibata et al. , 2001 ). In the fi rst step FAD is reduced to hydroperoxyfl avin, which is followed by electrophilic attack of oxygen from -OOH group on the double bond of squalene. As a result, 2,3-oxidosqualene is synthesized (Figure 1 ) (Ghisla and Massey , 1989 ; Massey , 1994 ; Entsh and van Berkel , 1995 ; van Berkel et al., 2006) .
There are several discrepancies between squalene and other known fl avin monooxygenases (Joosten and van Berkel , 2007 ) . Firstly, SE catalyzes epoxidation but not hydroxylation and does not contain cytochrome P450 as a prosthetic group and does not bind NADPH directly. The electron transfer is mediated by NADPH dependent cytochrome P450 reductase bound to microsomal membrane. Other fl avin monooxygenases bind the nicotinamide cofactor directly . These differences enhance the chances of designing drugs selective enough to lower cholesterol synthesis but not disturbing other fl avin monooxygenases dependent processes.
Specifi city of epoxidation reaction
The reaction catalyzed by squalene monooxygenase is highly specifi c (Nagumo et al. , 1995 ) . Only terminal double bonds of squalene are oxidized to 2,3-oxidosqualene and 2,3:22,23-dioxidosqualene subsequently. 5,6-Oxidosqualene and 10,11-oxidosqualene are not observed in the reaction catalyzed by SE (van Duuren and Schmitt , 1960 ; Abe et al. , 2007 ) . Oxidation of the terminal double bonds is characteristic for other enzymatic reactions (Lucas et al. , 2010 ) . Zeaxanthin epoxidase oxidizes double bonds only at the ends of zeaxantin, despite the fact that this substrate, like squalene, contains several internal double bonds which could be potentially epoxidized (Hieber et al. , 2000 ) .
The activity of enzyme towards squalene analogs was also checked (Abe et al. , 2007 ) . A lack of one double bond (5,6-dihydrosqualene, 10,11-dihydrosqualene) as well as two double bonds (6,7,18,19-tetrahydrosqualene, 10,11,14,15 -tetrahydrosqualene) of squalene do not preclude epoxidation of terminal isoprene units (Figure 2 ). An analog with an additional methyl group or its depletion at the epoxidation site of squalene does not inhibit the reaction (Corey and Russey , 1966 ; van Tamelen and Heys , 1975 ) (Figure 3 ). For example 2-methylbutylene and propylene ends are still epoxidized, but fi ve times less effi ciently than the 2-metylpropylene end. These results suggest that the enzymatic epoxidation is not strongly infl uenced by steric hindrance due to methyl groups even in the close vicinity of the oxidation site (van Tamelen and Heys , 1975 ) .
Structure-activity relationship
The alignment of amino acid sequence of squalene monooxygenses from different organisms shows a high sequence homo logy of 83 -93 % among the mammalian enzymes and 30.2 -35 % between fungal and mammalian SEs (Lee et al. , 2004 ) . Some differences were found between enzymes of pathogenic fungi. For example squalene monooxygenase from Trichophyton tonsurans is homologous in 95 % , 75 % , 74 % and 65 % , with Trichophyton rubrum , Emericell nidulans , Aspergillus fumigates and Aspergillus niger SEs, respectively (Table 1 ) (Motavaze et al. , 2008 ) . The high homology provides the possibility of fi nding an inhibitor with a broad spectrum of antifungal activity. However, signifi cant differences between mammalian and fungal squalene monooxygenases suggest they have different sensitivities to various inhibitors (Ruckenstuhl et al. , 2008 ) . Additionally, squalene monooxygenases of mammals and plants are more closely related to each other than fungal SE is to their mammalian counterparts, e.g., human SE shows 83 % of homology to Arabidopsis thaliana SQE1 but only 36 % to Saccharomyces cerevisiae and 25 % to Methylococcus capsulatus SEs (Table 1 ) (Nakano et al., 2003) .
Todate, squalene monooxygenases from rat (Ono and Imai , 1985 ; Denner -Ancona et al., 1995 ) , pig (Bai and Prestwich , 1992 ; Denner -Ancona et al., 1995 ) , liver microsomes, recombinant rat (Nagumo et al. , 1995 ; Sakakibara et al. , 1995 ) and human (Laden et al. , 2000 ) SEs have been purifi ed. These enzymes were unstable and tended to form aggregates, even in the presence of detergents (Lee et al. , 2004 ) , which are likely to impede the formation of crystals. Until recently a three-dimensional (3D) structure of SE had not yet been solved. Despite the low sequence similarity between squalene monooxygenases and other fl avoproteins, a signifi cant structural homology exists among them (Lee et al. , 2004 ) . The only fl avoprotein, for which a 3D structure has been solved, is p-hydroxybenzoate hydroxylase (PHBH) (Schreuder et al. , 1989 ) . Although PHBH and SEs share only about 20 % of sequence identity, three highly conserved sequence motifs are present in both enzymes (Ruckenstuhl et al. , 2005 ) . All of them participate in FAD binding. One of them, GxGxxG, is responsible for binding ADP moiety of FAD and is a part of Rossmann fold, which is characteristic for numerous nucleotides binding proteins. The other motif has the highly conserved GD residues, which contact the 3 -OH of the ribose moiety of FAD. The third one takes part in interactions with ribitol moiety of FAD and is conserved in all fl avoproteins (Eggink et al. , 1995 ) . The enzyme has no distinct binding domain of coenzyme NADPH (Wierenga et al. , 1986 ; Eggink et al. , 1995 ) , which is typical for class A fl avoprotein monooxygenases (van Barkel et al. , 2006 ) . NADPH forms a transient complex with SE, which disassociates immediately after FAD reduction (van Barkel et al. , 2006 ).
Site-directed mutagenesis of recombinant rat SE (Ruckenstuhl et al. , 2005 (Ruckenstuhl et al. , , 2008 and photolabeling (Lee et al. , 2000 (Lee et al. , , 2004 of short 24 amino acids peptides experiments showed that the active site of enzyme is moderately hydrophobic and located proximally to the FAD-binding motif. Conserved aromatic residues, through π -π interactions, help in the correct folding of the π -electron rich, hydrophobic substrate, and in this way affi rms the regio-and stereospecifi city of an epoxidation reaction. Analysis of a series of single amino acid mutants of rats ' squalene monooxygenase obtained for evaluation of the enzyme activity showed that almost all of them were less active than the wild-type enzyme (Abe et al. , 2007 ) .
Squalene monooxygenase inhibitors

Antimycotic compounds
Naftifi ne (1) (see Table 2 ) is the fi rst antifungal agent, which blocks biosynthesis of ergosterol, the crucial component of all fungal cell membranes, by inhibiting epoxidation of squalene (Georgopoulos et al. , 1981 ; Abe et al. , 1994 (Georgopoulos et al. , 1981 ; Ryder and Dupont , 1984 ; Kan et al. , 1986 ) . Currently it is used in the treatment of infections caused by pathogenic fungi, e.g., C. albicans and Trichophyton rubrum (Abe et al. , 1994 ) . It was a starting point for a series of successive squalene monooxygenase inhibitors (2 -11) ( Table 2 ). As a result of substitution of cinnamyl group in naftifi ne with a 6,6-dimethyl-2-hepten-4-ynyl, a 4-t-butylbenzyl, and a [4-(1-methyl-1-phentylethyl) phenyl]methyl terbinafi ne (2), butenafi ne (3), and SDZ SBA 586 (4) respectively, have been obtained. They have a higher inhibitory activity than the starting compound and are reversible, non-competitive inhibitors of C. albicans squalene monooxygenase with respect to squalene, FAD, NADH and NADPH (Ryder and Dupont , 1985 ; Abe et al. , 1994 ) . IC 50 values for mammalian SE are several orders of magnitude higher than for the fungal enzyme (e.g., IC 50 for terbinafi ne for C. albicans = 30 n m , for rat > 100000 n m ) (Ryder et al. , 1986 ) . It suggests that during antimycotic therapy they do not disturb the cholesterol biosynthesis pathway of the host. To search the terbinafi ne ' s structure-activity relationship its derivatives were synthesized and their potential to inhibit squalene epoxidation were checked (Favre and Ryder , 1997 ) .
Generally, replacement of naphthalene moiety of terbinafi ne (12-15) results in a loss of activity (Table 3 ) with one significant exception, , in which the presence of 3-chloro-7-benzo[b]thiophene group causes broadening of its antifungal activity (Favre and Ryder , 1997 ) . The removal of methyl group from the tertiary amine (16) or the substitutions Table 3 Antimycotic squalene monooxygenase inhibitors. Terbinafi ne and its derivatives (Ryder and Dupont, 1985; Abe et al., 1994 (Table 3 ) (Favre and Ryder , 1996 ) . Although terbinafi ne and its derivatives do not show any obvious structural similarities to squalene, FAD or NADPH, it seems that they act as substrate analogs (Abe et al. , 1994 ) . The point mutation studies of squalene monooxygenases from terbinafi ne resistant strains indicate amino acids critical for terbinafi ne-enzyme recognition (Laber et al. , 2003 ; Ruckenstuhl et al. , 2005 Ruckenstuhl et al. , , 2007 . They are located at the C-terminus (Phe402, Phe420, Phe430 and Phe433 residues in Saccharomyces cerevisiae SE) and in the central part of the enzyme (Leu251) (Laber et al. , 2003 ) . Based on a molecular docking detailed mechanism of the SE, inhibition by terbinafi ne was proposed. According to that model the inhibitor interacts with amino acids at C-terminus and the central part of the enzyme (Nowosielski et al. , 2011 ) . The naftalene ring interacts with residues in a small, highly hydrophobic cavity near the entrance to the substate's binding pocket. Tertbutyl substituent of terbinafi ne points toward the center of the enzyme blocking the main (one of two) entrance to the enzyme ' s catalytic site. This sustains the experimental evidence that terbinafi ne inhibits fungi SE in non-competitive manner (Favre and Ryder , 1996 ; Nowosielski et al. , 2011 ) .
Anticholesterolemic agents
Allylamines The extension of the carbon skeleton between the tertiary nitrogen and the naphthyl group or the substitution of phenyl group with naphthyl group in terbinafi ne increase specifi city of these compounds (19-23) toward mammalian SEs (Table 4 ) (Takezawa et al. , 1989 ) . A similar effect was observed for the substitution of the N-methyl group with ethyl (26) or propyl group (27) and the addition of heteroaryl moiety at position 3 of the phenyl ring [ Table 4 , (31) - (46)] (Takezawa et al. , 1989 (Takezawa et al. , , 1990 . NB-598 (47) is the fi rst compound obtained by chemical modifi cation of aromatic moiety of terbinafi ne (Horie et al. , , 1993 ; it is a highly-potent, competitive and specifi c inhibitor of mammalian squalene monooxygenase . This bis(thienyl) derivative strongly inhibits microsomal squalene monooxygenase from rat and dog livers, and the enzyme from the HepG2 cell line with IC 50 values of 4.4 n m , 2.0 n m , and 0.75 n m , respectively . It blocks cholesterol synthesis, but does not affect the synthesis of free fatty acids, phospholipids, and triacylglycerols. In rats and beagle dogs, NB-598 markedly lowers total cholesterol and increases squalene levels in blood serum.
NB-598 is a strongly lipophilic molecule. Its poor solubility correlates with poor permeation and absorption, which concomitantly limits its bioavailability and its potential usage as a drug (Lipinski et al. , 2001 ) . A lipophilic property of NB-598 was improved by modifying the thienyl-thienyl structure and introducing polar linker between terminal thiopene and aryl amine portion of the molecule [ Table 4 , (48) - (51)] (Sawada et al. , 2004 ) . Ether derivative (49) is more potent than ester one (48) and NB-598 (Sawada et al. , 2004 ) . Additionally, the substitution of geminal dimethyl moiety (49) with diethyl (51) showed that only methyl is effective at this position (Sawada et al. , 2004 ) . N-ethyl derivative is more than two times stronger than N-methyl and N-propyl analogs (Sawada et al. , 2004 ) . One of the most potent derivative is FR194738 (49). Compared to NB-598, it shows higher inhibitory activity, bioavailability and stability (Table 5 ) (Sawada et al. , 2004 ) . It inhibits cholesterol biosynthesis in HepG2 cells more potently than the clinically used HMG-CoA reductase inhibitors (e.g., simvastatin, fl uvastatin, pravastatin) (Sawada et al. , 2004 ) . In studies carried out on dogs, FR194738 demonstrated an ability of reducing triglyceride levels and plasma cholesterol in a dose-dependent manner. LDL cholesterol level is decreased more than HDL, resulting in an improved atherogenic index (LDL/HDL ratio) (Sawada et al. , 2004 ) . The reduction in triglyceride level is due to reduced secretion of VLDL, triglyceride rich particles. It is well tolerated up to 100 mg/kg (Sawada et al. , 2002 ) . It means that FR194738 could become a new drug for hypercholesterolemia therapy.
Further investigations resulted in the discovery of a new class of potent mammalian squalene monooxygenase inhibitors as silane derivatives of NB-598 [ Table 4 , (52) - (72)] (Gotteland et al. , 1995 (Gotteland et al. , , 1997 . IC 50 values between the phenyl (53) and cyclohexyl (52) analog indicates the importance of an aromatic moiety directly attached to silicon (Gotteland et al. , 1995 ) . Additionally, 4-substitution of phenyl ring with methoxy (54), thiomethyl (55), hydroxyl (56), thiol (57), carbamoyl (58), trifl uoroacetyl (59), ethynyl (60) moiety signifi cantly decrease, while fl uorine (61), methyl (62), formyl (63), cyano (64), or vinyl (65) residues improve the inhibitory potential of derivatives. Introduction of methyl (66), methoxy (67), trifl uoromethyl (68) and cyano (69) substituents in position 2 of the phenyl ring also improve activity. It is interesting that 3-methyl (70) substitution causes almost complete loss of activity, although methyl in 2 and 4 position of the ring increases affi nity of these derivatives into the enzyme (Gotteland et al. , 1995 ) . Further investigations showed that ene-yne nitrogen substituent (66) can be replaced by an yne-yne side chain (72) without signifi cant loss of activity. They resulted in (aryloxy)methylsilane derivatives (71), (72). The clue is that they not only effi ciently inhibit rat squalene monooxygenase in vitro , but they also block cholesterol biosynthesis in rats on oral administration (Gotteland et al. , 1995 ) . EC 50 values for these compounds are relatively low, which made them promising candidates for further hypercholesterolemic agents (Gotteland et al. , 1995 ) .
Squalene derivatives An additional approach in the search for new potent competitive inhibitors of squalene monooxygenase uses squalene analogs as a starting point. Several squalene derivatives with different proximal groups and with extended and truncated carbon skeletons have been tested however, until now few of them inhibit squalene epoxidation (Table 6 ) (Sen and Prestwich , 1989b ; Sen et al. , 1990 ) . The entire trisnorsqualenoid moiety is necessary to achieve an inhibitory effect. Both addition and removal of isoprene units in trisnorsqualenoid moiety, and even the removal of its terminal isopropylidene group cause a dramatic Table 4 Anticholesterolemic squalene monooxygenase inhibitors. Terbinafi ne ' s derivatives (Takezawa et al., 1989; Gotteland, 1995 (Sen and Prestwich , 1989b ) , which acts as a substrate analog, mimicking a reactive intermediate of squalene epoxidation (Sen and Prestwich , 1989b ) . Compounds (76) and (77) also inhibit squalene monooxygenase (the fi rst one 10-fold weaker than TNSA, the second one as potent as TNSA) (Table 6 ). It is possible that the primary OH group of both of them and of TNSA adopt the same spatial orientation when they bond to the enzyme, perhaps mimicking the transition state of epoxide formation (Sen and Prestwich , 1989b ) . Other moderately active analogs are TNS hydroperoxide (78), TNS thiol (79), TNS cyclopropylamine (80) ( Table 6 ) (Sen and Prestwich , 1989a,b ) . Difl uoroolefi ns are another squalene derivative with SE inhibiting potential (81), (82) ( Table 6 ) (Moore et al. , 1992 ) . Both difl uoroolefi n (81) and symmetrical tetrafl uoro analogue (82) are recognized by the enzyme (Moore et al. , 1992 ) . However, the homomethylene (CHC = CF 2 ) and stericallyhindered analog (CH 3 C = CF 2 ) did not inactivate the enzyme. It points at the orientation of difl uoro group in the active site (Sen and Prestwich , 1989a ) . The time-dependent competition with squalene, and structure-activity relationship data suggest that difl uoroolefi ns binds covalently to the enzyme (Moore et al. , 1992 ) . The advantage of difl uoro compounds is that they are active in mice after oral administration (Jarvi et al. , 1991 ) .
Several squalene analogs with substituted C-26 methyl group (83)-(85) are competitive inhibitors of squalene monooxygenase (Table 6 ) (Bai , 1991 ) . They act as substrates for the enzyme and are converted into 2,3-and 22,23-epoxides. IC 50 values for the most potent inhibitors (83-85) for pig liver SE amount to 10 µ m, 70 µ m and 109 µ m, respectively (Table  6 ) (Bai , 1991 ) .
Natural compounds and their derivatives Plants, fungi and higher animals are a wealthy source of pharmacologically valuable leading compounds. Over 300 plant extracts, mostly of herbs, which according to folk herbalism decrease cholesterol level, were tested for SE inhibition activity (Gurib -Fakim, 2006 ) . Extracts from Agrimonia pilosa (Agrimony) , Aleurites fordii (Tung tree) , Euphorbia jolkini Squalene derivatives (Sen and Prestwich, 1989a,b; Sen et al., 1990; Bai, 1991; Jarvi et al., 1991; Moore et al., 1992) .
(Euphorbia) , Lagerstroemia indica (Crape myrtle) , Myrica rubra (Chinese strawberry) (IC 50 = 1 µ g/ml), Camellia sinensis (Chinese camellia) , Allium sativum (Garlic), Rheum palmatum (Rhubarb), Cynara scolymus (Artichoke), Fraxinus excelsior (European Ash), and Peumus boldus (Boldo) show a signifi cant inhibitory potential to SE (Abe et al. , 2000b,c ; Gupta and Porter , 2001 ; Bundy et al. , 2008 ) . One of the most thoroughly investigated is extract obtained from green tea. Its major component (-)-epigallocatechin-3 -O-gallate (EGCG) (86) and a few other polyphenols, e.g., (-)-epicatechin-3-O-gallate (ECG) (87), (-)-epigalloca techin (EGC) (88), theasinensin A are very effi cient inhibitors of squalene epoxidation (Abe et al. , 2000c ) (Table 7 ) . Other good prospective natural galloyl compounds, such as galloyl fl avanols, galloyl proanthocyanidines, galloyl glucoses and ellagitannins have been found in other plant extracts. Several of them inhibit squalene epoxidation as effi ciently as EGCG and they are also a starting point for the synthesis of new active compounds. Numerous gallic acid derivatives, such as alkyl gallates, gallolyl esters of isoprenoids, gallolyl amide and n-alkyl esters of hexahydroxydiphenol (HHDP)-dicarboxylic acid containing n-alkyl gallate dimeric structure have been synthesized (Abe et al. , 2000a (Abe et al. , , 2001 . Dodecyl gallate (DG) (92) showed the strongest inhibition toward recombinant rat and pig SEs (IC 50 = 0.061 µ m ). It is about 10 times more potent than previously mentioned, naturally occurring EGCG (IC 50 = 0.69 µ m ) and over 1000 times more than the gallic acid (90) (IC 50 = 73 µ m ).
There are a few putative mechanisms of EGCG ' s healthpromoting activity. It exhibits a strong capacity for scavenging exogenous H 2 O 2 , reactive oxygen and nitrogen species and also protects against them by activation of several cellular antioxidant mechanisms . However, some data suggest that EGCG by itself generates H 2 O 2 participating as mediator in cellular signaling, proliferation, and differentiation (Forman et al. , 2004 ) . Other data points out that EGCG causes the generation of superoxide radical anions (O 2
• -), which promote production of hydroxyl radicals ( · OH) in the Fenton reaction. Following this assumption, the inhibitory effect could be a result of high reactivity of the aforementioned radicals (Nakagawa et al. , 2004 ; Elbling et al. , 2005 ) . Other reports indicate that EGCG specifi cally inhibits squalene monooxygenase (Abe et al., 2000a ) and telomerase (Noguchi et al., 2006 ) , and specifi cally regulates the expression of VEGF, matrix metalloproteinases, uPA, IGF-1, EGFR, cell cycle regulatory proteins and inhibits NFk B, PI3-K/Akt, Ras/Raf/MAPK and AP-1 signaling pathways (Shankar et al., 2007 ) . However, it raises doubts as to whether one compound could regulate so many different and unrelated factors.
Another noteworthy source of natural SE inhibitors is garlic. Data from animal studies (Chi et al. , 1982 ; Quereshi et al. , 1983 ) , clinical trials (Adler and Holub , 1997 ; Bordia et al. , 1998 ) , meta-analyses (Warshafsky et al. , 1993 ; Silagy and Neil , 1994 ; Stevinson et al. , 2000 ) and cell culture studies (Gebhardt , 1993 ; Cho and Xu , 2000 ; Liu and Yeh , 2000 ) show that garlic extract signifi cantly lowers the cholesterol level in plasma. Garlic compounds inhibiting squalene monooxygenase activity can be divided into three groups: selenium compounds (Ip et al. , 1992 (Ip et al. , , 2000 McSheehy et al. , 2000 ) , tellurium compounds (Schroeder et al. , 1967 ) and allyl compounds (Gupta and Porter , 2001 ) (Table 8 ) . Four selenium compounds [selenocystine (97), selenite (98), (Table 8 ) (Gupta and Porter , 2001 ). The removal of allyl group results in the loss of inhibitory activity of these compounds (Gupta and Porter , 2001 ). Monothiols and dithiols reverse the inhibitory activity of selenite and methylselenol, which indicates that they react with sulfhydryl groups on protein.
The inhibitory activity of tellurium, selenocystine and garlic compounds containing allyl groups could be reversed only by dithiols which means that they bind to two vicinal cysteines (Gupta and Porter , 2001 ; Laden and Porter , 2001 ). However, selectivity of allyl derivatives towards SE is low. There are several studies demonstrating that they interact with many other proteins (Hanther , 1968 ; Bjornstedt et al. , 1996 ; Barbosa et al. , 1998 ; Park et al. , 2000 ) . Moreover, allyl compounds cross through the blood-brain barrier and inhibit SE in Schwann cells blocking myelin formation, leading as a consequence to peripheral segmental demyelination and paralysis (Wagner -Recio et al., 1991 ; Ammar and Couri , 1992 ; Stowe et al. , 1992 ) . It excludes them as candidates for cures in modern therapy.
Current strategies for lowering cholesterol level in blood
There has been a long-standing debate regarding the main, underlying causes of cardiovascular diseases. It started in late 1950s, 10 years after the epidemiological approach of cardiovascular disease was innovated. As a result, a correlation between elevated concentrations of plasma cholesterol and the development of coronary heart disease (CHD) became apparent (Kannel , 1995 ) . It gave a birth to the lipid hypothesis, which suggests that lowering cholesterol reduces the risk of coronary events (Newland , 1976 ) . Further investigations indicated that coronary heart diseases are associated mainly with low-density lipoprotein (LDL) cholesterol, whereas high-density lipoprotein (HDL) cholesterol is inversely correlated with CHD. In 1984, the National Institute of Health (NIH) Coronary Primary Prevention Trial approved that lowering elevated LDL cholesterol with diet and drugs would reduce the risk of CHD (NIH Consensus Development conference , 1985 ). Further trials disclosed that a lowering of plasma total cholesterol by 10 % and of LDL cholesterol by 40 mg/dl are followed by a 25 % and 20 % reduction in CHD incidence, respectively (Baigent et al. , 2005 ) . Therefore, currently LDL levels are the most common marker in determining cardiovascular risk and LDL particles are the most desired target of hypercholesterolemia therapy (Contoids et al. , 2009 ; Sandeep and Davidson , 2011 ) . Elevated LDL cholesterol levels are a result of perturbations in its metabolism (Toutouzas et al. , 2010 ) . Cholesterol homeostasis is a derivative of cholesterol intake, secretion, resorption and its de novo synthesis (Yamamoto and Bloch , 1970 ; Brown and Goldstein, 1976) and is regulated at both transcriptional and post-transcriptional levels (Goldstein and Brown , 1990 ; Brown and Goldstein , 1997 ; Kathryn et al. , 2010 ) . Understanding the mechanism of controlling cholesterol homeostasis enables us to choose new targets of hypercholesterolemia therapy.
Current strategies to control cholesterol levels in blood are based on: (i) restriction of cholesterol intake from the food (diet) (Micallef and Garg , 2009 ), (ii) reduction of cholesterol and bile acids absorption from the gut (ion-exchange resins (Ginsberg , 1995 ) , microsomal triglyceride transport protein (MTP) inhibitors (Cuchel et al. , 2007 ) , Niemman-Pick C1 Like 1 protein inhibitors, (iii) inhibition of de novo cholesterol synthesis (statins, squalene synthase, 2,3-oxidosqualene cyclase, squalene monooxygenase inhibitors) (Endo et al. , 1976 ; Grundy , 1988 ) , (iv) inhibition of LDL particles formation (proprotein convertase subtilisin/kexin type 9 (PCSK9) antisense oligonucleotides) (Rizzo , 2010 ), (v) increasing the number of LDL receptors (enhancers of LDL receptors synthesis and inhibitors of its degradation) (Boguslawski, 1993 ; Lagace et al. , 2006 ; Graham et al. , 2007 ; Shan et al. , 2008 ) , and (vi) raising high-density lipoprotein levels (cholesteryl ester transfer protein (CETP) inhibitors) (Barter et al. , 2007 ) . All of these are sophisticated but none of them fully cover patients ' demands (Katsnelson, 2010 ) . There is constant need for new strategies. Thorough analysis of strengths and weaknesses of current strategies could help to provide direction for further investigations.
An increase in the availability of new food choices and in energy intake, sedentary lifestyle, and poor eating habits has led to an increase in obesity and associated metabolic diseases. Dietary habits are changing, particulary in regards to the intake of sugar-rich foods and drinks and animal fats (Pan et al. , 2011 ) . Daily cholesterol consumption is approximately 500 mg and it is even two times higher than average in developing countries (Callejo Gimenez et al. , 2003 ) . Cardiovascular prevention must therefore target sedentary lifestyle, excess weight, and favor low-calorie, low-fat diet and natural compounds with potential cardiovascular benefi ts, such as phytosterols, omega-3 fatty acids (Butt et al. , 2009 ; Micallef and Garg , 2009 ; Smart et al. , 2011 ) . Therapeutic education holds a growing and complementary role in the public health system (Baudet et al. , 2011 ) . Limitation of cholesterol intake is the primary strategy of regulating cholesterol levels in blood, however it is diffi cult to implement to therapy mainly because of deep-rooted bad eating habits.
The reduction of bile acids resorption from the intestine is another aim of the modern antihypercholesterolemic therapy. Approximately 50 % of consumed cholesterol is absorbed (Heinemann et al. , 1993 ) . Ion-exchange resins, the fi rst hypercholesterolemic drugs, trap bile acids and then, are excreted from body as a complex. It interrupts enterohepatic circulation of cholesterol and its derivates and as a consequence lowers LDL-cholesterol by 10 -15 % (Black , 2002 ) . They have no major effect on HDL-cholesterol and triglycerides, however, there is evidence of their moderate benefi cial effect on the cardiovascular endpoint (The Lipid Research Clinics Coronary Primary Prevention Trial results , 2002 ). The main disadvantage of resins is a low tolerability because of gastrointestinal side effects (Drexel , 2009 ) .
There is some evidence that microsomal triglyceride transport protein (MTP) could be the target of future therapy (Hussain et al. , 2011 ) . It is an endosomal protein, which catalyzes the assembly of cholesterol, triglycerides, and apoliporotein to very low-density lipoprotein (VLDL) or chylomicrons. Inhibition of MTP in the intestine blocks fat absorption and in the liver reduces hepatic secretion of VLDL. It causes signifi cant LDL cholesterol and triglycerides reductions, but also causes hepatic steatosis and other gastrointestinal adverse effects, due to a hepatic accumulation of triglycerides (Cuchel et al. , 2007 ; Rizzo , 2010 ) . Still, AEGR-733 and lomitapide, small molecule MTP inhibitors, are being used in some cases in patients who cannot achieve therapeutic treatment on the available regimens or suffer from intolerance to statins (Davidson , 2009 ) . The regulation of MTP takes place at transcriptional, post-transcriptional and post-translational levels by macronutrients, hormones and other factors and could be an option to reduce plasma lipids (Hussain et al. , 2011 ) .
Ezetimibe, a cholesterol absorption inhibitor, is another promising drug candidate. It is glucuronidated in intestine and liver, localized at the brush border of the small intestine, where it binds to Niemman-Pick C1 Like 1 protein. This protein blocks cholesterol absorption by 54 % and increases the fecal excretion of neutral sterols by 72 % cholesterol without affecting the absorption of triglycerides, bile acids and fat-soluble vitamins (Knopp et al. , 2001 ; van Heek et al. , 2001 ; Sudhop et al. , 2002 ) . After 2 weeks of treatment (10 mg ezetimide/day) LDL-cholesterol decreased by 20.4 % (Sudhop et al. , 2002 ) . A weak correlation between the percent of reduction of LDLcholesterol and cholesterol absorption is the result of boosted (by 89 % on ezetimide relative to placebo) cholesterol synthesis, which compensates the inhibition of cholesterol absorption (Sudhop et al. , 2002 ) . This rise in cholesterol synthesis may explain why ezetimide does not reduce cardiovascular events (Landmesser et al. , 2005 ; Kastelein et al. , 2008 ) .
However, administration of ezetimibe and its analogs with statins (inhibitors of cholesterol synthesis) could give more benefi ts. It is a highly acclaimed treatment option for patients with hypercholesterolemia (Ballantyne et al. , 2003 , Yubin et al. , 2011 .
Statins are the most common and strongest drugs of modern anti-hypercholesterolemic therapy. They inhibit HMG-CoA reductase, a key enzyme from the cholesterol biosynthesis pathway (Stancu and Sima , 2001 ) . A reduction of de novo cholesterol synthesis results in reduced intracellular cholesterol levels. It causes upregulation of the LDL-receptor (Reihner et al. , 1990 ) , and eventually lowers LDL-cholesterol in blood, with an average of 33 % , and even by 50 % in the case of atorvastatin (80 mg/day) and rosuvastatin (20 -40 mg/day) (LaRosa et al. , 2005 ; Drexel , 2009 ) . Some studies suggest that benefi ts of a treatment with statins may not be entirely due to their effects on LDL cholesterol. It is postulated that statins possess anti-infl ammatory, antioxidant, and antithrombotic activity (Liao , 2005 ; Ray et al. , 2006 ; Sadowitz et al. , 2010 ) .
Long statins administration boosts the expression of HMG-CoA reductase and other enzymes from the cholesterol synthesis pathway, making it necessary to increase the dose of cure to achieve the therapeutic effect Goldstein, 1979 , 1980 ; Grundy , 1988 ) . Inhibition of HMGCoA reductase results in mevalonate depletion (Naoumova et al. , 1996 ) , which disturbs the synthesis of isoprenoid derivatives, such as dolichol, ubiquinone (Co-enzyme Q10), heme A, isopentenyl adenosine and prenylated proteins (Figure 4 ) (Schafer and Rine, 1992 ; Ghirlanda et al. , 1993 ) . It responds with severe side effects, such as, myalgias, muscle cramps, polyneuropathy myositis and myopathy with incidence of rhabdomyolysis, neuropathy, and cognitive defects, as well as liver and kidney disorders (Edison and Muenke , 2004 ; Armitage , 2007 ) . Cerivastin as one of the most promising statins has caused the deaths of 35 patients and was withdrawn from the market (Igel et al. , 2001 ). Due to side effects statins are not recommended for patients with liver, renal and heart failures, for children, elderly people and pregnant women (Edison and Muenke , 2004 ; Armitage , 2007 ) .
The administration of ezetimibe with statins helps to suffi ciently reduce LDL-cholesterol with lower doses of statins. For example, an application of 10 mg of ezetimibe to atorvastatin allows a reduction in the statin dose from 80 to 10 mg/day (Ballantyle et al., 2003) . Therapy combining mode of action of these remedies (inhibition of cholesterol synthesis by statin and cholesterol absorption across the intestinal wall by ezetimibe) provides substantial incremental reduction in total and LDLcholesterol and triglycerides (Ballantyle et al., 2003) . It may reduce statin doses in clinical practice, which is extremely important taking into account the severe side effect of these agents.
Inhibition of cholesterol synthesis at the stage beyond HMG-CoA reductase, downstream of farnesyl pyrophosphate is another approach. It could spare isoprenoid synthesis, avoid mevalonate depletion, and in turn, statin-derived adverse effects. It is also desirable to block the enzyme, which is located in the pathway upstream lanosterol biosynthesis in order to avoid the accumulation of intermediate products which are toxic in high concentration. These requirements are fulfi lled by three enzymes: squalene synthase (Ugawa et al. , 2000 ) , 2,3-oxidosqualene cyclase (van Sickle et al. , 1992 ) and squalene monooxygenase.
Squalene synthase catalyzes the reductive dimerization of farnesyl-diphosphate to squalene, thereby diminishes hepatic cholesterol synthesis and upregulates LDL receptors. However, the safety profi le of currently known squalene synthase inhibitors is of concern. They cause elevation of several liver enzymes levels, probably because farnesyl-diphosphate is converted into toxic farnesol-derived dicarboxylic acid (Ugawa et al. , 2000 ) . It is unlikely that this enzyme will be a target for future drugs (Davison, 2009 ).
An advantage of 2,3-oxidosqualene cyclase as a target for hypercholesterolemia therapy is that partial inhibition of that enzyme causes accumulation of 2,3-oxidosqualene and 2,3:22,23-dioxidosqualene. They are converted into 24,25-epoxycholesterol, which decreases the transcription level of HMG-CoA reductase gene and stimulates degradation of this enzyme. Numerous 2,3-oxidosqualene cyclase inhibitors have been found (van Sickle et al. , 1992 ) , however, none of them have been approved as clinical drugs for the treatment of hypercholesterolemia because of the toxicological issues (Watanabe et al. , 2010 ) .
Among the enzymes from cholesterol synthesis pathway squalene monooxygenase seems to be the best candidate for a target of hypercholesterolemia therapy. SE inhibition does not cause the cytotoxic effect, typical for the inhibition of enzymes from cholesterol biosynthesis pathway downstream lanosterol synthesis (Fernandez et al. , 2005 ) . Cholesteroldependent degradation of squalene monooxygenase proves that this enzyme is a control point in cholesterol synthesis, beyond HMG-CoA reductase (Gill et al. , 2011 ) .
The effective therapy of reduction cholesterol level should combine several approaches. It should be as effective as statins in the reduction of cholesterol de novo synthesis, but devoid of their side effects. The best way to meet these requirements is to inhibit the squalene monooxygenase activity or silence its gene transcription supported by other approaches such as, diet, inhibition of cholesterol and bile acids absorption, reduction of LDL particles formation by antisense oligonucleotides directed against proprotein convertase subtilisin/kexin type 9 (PCSK9) (Frank-Kemenetsky et al. , 2008 ; Rizzo , 2010 ) or against apolipoprotein B-100 (apoB) -mipomersen (Crooke et al. , 2005 ; Patel and Hegele , 2010 ) , increasing number of LDL receptors (enhancers of LDL receptors synthesis and inhibitors of its degradation) (Lagace et al. , 2006 ; Grahan et al., 2007; Shan et al. , 2008 ) and other cholesterol transporters (ATP-binding cassette proteins) (Quazi and Molday , 2011 ) , and raising high-density lipoprotein levels [cholesteryl ester transfer protein (CETP) inhibitors (Barter et al. , 2007 ; KuangYuh, et al., 2011 ) ]. Most of them are still under investigation. Recently miRNAs (miR-33, miR122, miR-370) involved in post-transcriptional regulation of lipid metabolism genes have been identifi ed. It has opened new possibilities for treatment of hypercholesterolemia (Kathryn et al. , 2010 ) .
Safety of hypercholesterolemia therapy
Therapy based on inhibitors of cholesterol biosynthesis through the prism of cellular functions of cholesterol (Simons and Ehehalt , 2002 ) and disorders of its synthesis (Hermann , 2003 ) , raises some doubts and concerns. Cholesterol is a key component of cell membranes and the precursor of all steroid hormones and bile acids. It can be converted to oxycholesterol that can act as a regulatory signaling molecule involved in numerous developmental processes (Mann and Beachy , 2000 ) . Additionally, intermediates of cholesterol biosynthesis pathway are tied to a variety of important cellular functions, especially pre-squalene isoprenoid intermediates, where depletions cause numerous severe dysfunctions as mentioned above. It confi rms that inhibition of cholesterol synthesis in the post-squalene half of the pathway, e.g., at the stage of squalene epoxidation could give better therapeutic effect than using statins. However, defects in post-squalene cholesterol biosynthesis could cause some dysfunctions as well. Seven disorders involving post-squalene enzymes ' defects have been described recently -Smith-Lemli-Opitz syndrome, desmosterolosis, X-linked dominant chondrodysplasia punctate, CHILD syndrome, lathosterolosis, Greenberg skeletal dysplasia and Antley-Bixler syndrome (Hermann , 2003 ) . The pathogenesis of these disorders results mainly from accumulation of toxic sterol intermediates above each enzyme block and abnormal feedback regulation of earlier steps in the pathway, including the synthesis of key isoprenoid compounds, not from reduced plasma cholesterol levels. It is thought, that lowered below average plasma cholesterol levels do not respond for symptoms, such as growth and mental retardation, poor feeding in infancy, skeletal abnormalities, cholestatic liver disease, renal anomalies, congenital sensorineural hearing loss, structural CNS malformations, and embryonic lethality typical for some of these disorders (Hermann , 2003 ) . In preliminary experiments, it has been shown that cholesterol levels in tissues in embryos bearing defects related with cholesterol synthesis near the time of death are normal, presumably as a result of its placental transport from the mother (Caldas et al. , 2005, Hermann, unpublished ) . It confi rms the validity of assumptions that therapy based on inhibitors of cholesterol synthesis could be safe. That is because cellular cholesterol depletion is a result of diminished cholesterol synthesis and is supplemented by cholesterol from plasma. It helps to maintain tissues in proper conditions, and reduce cholesterol levels in plasma, which allows a therapeutic effect to be achieved. Substrate accumulation is a major danger in enzyme inhibition therapy. Inhibition of squalene monoxygenase results in squalene accumulation. Although some reports suggest that excessive intake of squalene (20 g/kg/day) causes neural damage in rats (Gajkowska et al. , 1999 ) , and lipoid pneumonia in a human patient (Asnis et al. , 1993 ) , there is generally thought that squalene has a positive effect on human health (Kelly , 1999 ) . About 60 % of dietary squalene is absorbed and up to 90 % of it is transported in serum (Strandberg et al. , 1990 ) . Even though a high intake of dietary squalene (200 -400 mg/day in the Mediterranean countries in comparison to USA -30 mg/day) increases its concentration in plasma and a part of its pool is converted into cholesterol, a positive effect of high intake of squalene on LDL and triglycerides (TG) levels has been proved (Strandberg et al. , 1990 ) . It was shown that consumption of 860 mg squalene daily for 7 -30 days increased its concentration 17 times in blood. However, the cholesterol level was affected only slightly. Longer therapy, up to 20 weeks, reduced cholesterol, LDL and TG concentrations of 17 % , 22 % and 5 % , respectively (Chan et al. , 1996 ) . Squalene signifi cantly enhances the fecal excretions of cholesterol, its non-polar derivatives and bile acids. At the same time it causes, due to negative feedback regulation, an inhibition of HMG-CoA reductase activity (Strandberg et al. , 1990 ) . Finally, squalene potentiates the cholesterol-lowering effect of statins, e.g., pravastatin (Chan et al. , 1996 ) .
Squalene has an excellent safety profi le (Christian , 1982 ; Fox , 2009 ) . Injected squalene (21 mg) into over million cases (including infants) showed very low incidence rate of side effects (mostly pain at injection site) (Ketomaki et al. , 2004 ) . Nearly 10 years ago antibodies to squalene were detected in the blood of veterans of the Gulf War (Gronseth , 2005 ) . As a result a discussion about the safety of using squalene as an adjuvant of vaccines arose. However, further clinical trials proved that squalene is poorly immunogenic (Lippi et al., 2001 ). Squalene ' s safety profi le as a vaccine adjuvant is well documented (Schultze et al. , 2008 ) .
A serum pool of squalene is distributed ubiquitously in tissue (Strandberg et al. , 1990 ) . The greatest concentration of squalene is in the skin, where it functions as a quencher of singlet oxygen, protecting it against exposure to UV and other sources of radiation (Kelly , 1999 ) . As a result of prolonged, high-dose oral administration it could also accumulate in the liver (Kamimura et al. , 1989 ) . Metabolic studies of squalene in tissues indicate that about 80 % of cellular squalene is metabolically inactive and deposited in a neutral lipid droplet, while the remaining 20 % is bound to the microsomal membranes. Additionally, only 10 % of the newly synthesized squalene is used in cholesterol synthesis (Tilvis et al. , 1982 ) . Therefore, squalene accumulated in response to squalene monooxygenase inhibition is non-toxic for cells even at high concentration (Chan et al. , 1996 ) .
Conclusions
Cholesterol plays a crucial role in all eukaryotic cells (Bloch , 1979 ) . In vertebrates, it is an important structural component of cellular membranes, precursor of oxysterols, steroid hormones and bile acids. It regulates embryogenesis and development (Xu et al. , 2005 ) . Cellular cholesterol is strictly controlled by multiple pathways (Chang et al. , 2006 ; Goldstein et al. , 2006 ) . The disturbance of its synthesis causes several severe dysfunctions. Up until now, eight distinct inherited disorders as a result of defects in the isoprenoid/cholesterol biosynthetic pathways have been identifi ed (Waterham , 2006 ) . Patients show a broad spectrum of severe symptoms, which are a result of abnormally increased/decreased levels of intermediate metabolites, but not reduced cholesterol levels (Waterham , 2006 ) .
High cholesterol concentration has been recognized as one of the most important predictors of arthrosclerosis and coronary heart disease. The far-reaching consequences of dyslipidemia have led to heart disease, diabetes, obesity, the metabolic syndrome, stroke, and non-alcoholic fatty liver disease (Pearson , 2004 ) . Additionally, accumulation of cholesterol and other lipids in late endosomes/lysosomes causes neuronal degradation, and it is known as Niemann-Pick disease type C (Arora et al. , 2010 ) . So the main goal for therapeutic intervention is normalization of cholesterol levels in the blood. There is abundant evidence that the reduction of cholesterol concentration lowers morbidity and mortality from the mentioned diseases (Downs et al. , 1998 ) .
Currently, the most popular drugs for treatment of hypercholesterolemia, which have dominated the lipids therapy market, are statins, HMG-CoA reductase inhibitors. Although they are effective in most cases, they cause several adverse effects as well. Studies on new approaches of lowering cholesterol levels are highly desired. There is some evidence that squalene monooxygenase could be the target of future hypercholesterolemia therapy. Inhibitors of this enzyme act further downstream in the cholesterol pathway than statins, which prevent the disturbance in the synthesis of mevalonate derivatives, such as dolichol, ubiquinone, heme A, and isoprenylated proteins. It avoids the side effects caused by their depletion which is typical for therapy with statins.
Up until now several potent squalene monooxygenase inhibitors, e.g., allylamines [FR194738, NB-598, theirs aryloxy(methylsilane)], squalene analogs (trisnorsqualene alcohol), and several natural, selenium and tellurium compounds, have been found. They decrease LDL levels in a dosedependent manner in HepG2 cells, L6 myoblasts, rat, hamster, and dogs similarly or even greater than statins (Hidaka et al. , 1991 ; Chugh et al. , 2003 ) . Additionally, they decrease triglyceride and increase HDL levels and do not affect HMGCoA reductase activity (Chugh et al. , 2003 ) . However, in the case of a high dose of tellurium compounds, their benefi cial features in SE inhibition were quenched by an unsatisfactory safety profi le. Their increased ( > 0.1 % of diet) prolonged exposure causes demyelination of the pheripheral nervous system, possibly due to decreased cholesterol synthesis, but also by downregulation of mRNA level of P0 protein being a crucial component of myelin (Katsuno et al. , 2009 ) . Due to the blood-brain barrier the level of brain cholesterol is independent from fl uctuations of the pool circulating in blood as a result of diet or medication. Hence, it is possible to decrease its level in serum without changes in the brain. It is extremely important taking into account the fact that low cholesterol amount in the brain is supposed to be responsible for a range of neurodegenerative disorders (Katsuno et al. , 2009 ). This SE inhibitor showed dermatosis-like toxicity in dogs, possibly due to the accumulation of squalene in skin cells . Additionally, antibodies to squalene have been detected in the blood of veterans of the Gulf War (Gronseth , 2005 ) , however, eventually allegations of safety concerns were rejected (Lippi et al. , 2010 ) . Taking into account the healthy properties of squalene there is a chance that squalene monooxygenase could be an alternative approaches to old targets in hypercholesterolemia therapy (Chugh et al. , 2003 ) . Previous results hold promise for the prevention of cardiovascular diseases with squalene monooxygenase inhibitors, however, clinical trials need to be carried out.
